Hironic Co

Hironic Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Hironic Co (149980.KQ) as of Oct 23, 2026 is -44.78. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 29.79 — a change of -250.32% (lower).

EV/FCF

-44.78

YoY

-250.32%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Hironic Co is 2025 -44.78 . EV/FCF (Enterprise Value to Free Cash Flow) of Hironic Co was 2024 29.79 . It decreases by -250.32% lower compared to the previous year.

The Hironic Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-28.76 KRW
Jan 1, 2019
25.57 KRW
Jan 1, 2020
23.93 KRW
Jan 1, 2021
-79.04 KRW
Jan 1, 2022
21.98 KRW
Jan 1, 2023
-53.64 KRW
Jan 1, 2024
29.79 KRW
Jan 1, 2025
-44.78 KRW
The Hironic Co EV/FCF history
YEAREV/FCFYoY
-44.78-250.32%
29.79-155.53%
-53.64-344.04%
21.98-127.81%
-79.04-430.31%
23.93-6.43%
25.57-188.93%
-28.76-110.84%
265.26-943.74%
-31.44+191.31%
-10.79-142.21%
25.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hironic Co Stock analysis

What does Hironic Co do? Hironic Co., Ltd. generates revenue through the manufacture and sale of medical equipment for skin and obesity care. The company's product lineup includes MIXEL, designed for treating skin lesions and melasma while enhancing skin texture and tone; MIPL, which addresses pigmentation, wrinkles, vascular issues, acne, and hair removal; MIDEPI, a dedicated hair removal device; DOUBLO, used for skin tightening, rejuvenation, and non-invasive facial and eyebrow lifting; MICOOL, for natural fat cell destruction; and New Midas, targeting body contouring and facial lifting. These products are sold to medical facilities and clinics specializing in dermatology and cosmetic treatments, with a focus on skin and obesity care segments. The company's revenue streams are derived from direct sales of its branded medical devices to healthcare providers. MIXEL and MIPL cater to dermatological treatments, while MIDEPI and MICOOL serve aesthetic and body contouring markets. DOUBLO and New Midas are positioned for non-invasive cosmetic procedures, appealing to clinics seeking advanced solutions for skin tightening and facial rejuvenation. Hironic's product portfolio targets both skin treatment and obesity care, aligning with the growing demand for specialized medical equipment in these sectors. Hironic Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hironic Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Hironic Co is -44.78 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Hironic Co changed from 29.79 to -44.78, representing a -250.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Hironic Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Hironic Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Hironic Co

All Key Metrics — Hironic Co